A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Clinical trial NCT07543744 · RECRUITING
Trial details
- NCT number
- NCT07543744
- Sponsor
- R-Pharm
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-17
- Primary completion
- 2026-05-15
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.